

August 12, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir,

Sub: Outcome of the Board Meeting held on August 12, 2023.

The Board of Directors of the Company at its meeting held today, August 12, 2023, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2023, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company.

The Board meeting commenced at 3.30 p.m. and concluded at 5.40 p.m.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

152
AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ millions, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023					
	Particulars	Quarter ended			Year ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Unaudited	Unaudited (Refer note 6)	Unaudited	Audited
A	Continuing Operations:				
1	Revenue from operations				
	(a) Net sales/ income from operations	23,635.3	23,717.3	17,304.7	83,715.4
	(b) Other operating income	272.9	345.0	111.8	854.6
	Total revenue from operations	23,908.2	24,062.3	17,416.5	84,570.0
2	Other income				
	(a) Foreign exchange gain (net)	337.4	497.9	-	695.3
	(b) Others	611.4	2,301.7	378.8	3,734.3
	Total other income	948.8	2,799.6	378.8	4,429.6
3	Total income (1+2)	24,857.0	26,861.9	17,795.3	88,999.6
4	Expenses				
	(a) Cost of materials consumed	13,752.6	12,741.5	9,341.9	46,667.2
	(b) Purchase of stock-in-trade	155.3	152.2	388.4	892.3
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(162.5)	(733.6)	(369.3)	(2,639.5)
	(d) Employee benefits expense	2,360.6	2,169.8	2,260.9	8,904.7
	(e) Finance costs	315.9	317.7	50.9	745.7
	(f) Foreign exchange loss (net)	-	-	5.0	-
	(g) Depreciation and amortisation expense	596.3	666.8	560.1	2,432.6
	(h) Other expenses	3,578.4	3,973.0	3,667.2	15,655.5
	Total expenses	20,596.6	19,287.4	15,905.1	72,658.5
5	Profit before tax from continuing operations (3-4)	4,260.4	7,574.5	1,890.2	16,341.1
6	Tax expense				
	Current tax	1,163.0	1,613.6	632.4	4,120.0
	Deferred tax	(82.6)	(24.2)	(99.9)	(233.6)
	Total tax expense	1,080.4	1,589.4	532.5	3,886.4
7	Profit for the period from continuing operations (5-6)	3,180.0	5,985.1	1,357.7	12,454.7
B	Discontinued Operations: (Refer note 5)				
8	Profit/(loss) before tax from discontinued operations	240.5	585.8	(189.5)	(197.6)
9	Tax expense from discontinued operations	61.0	122.9	(53.4)	(47.0)
10	Profit/(loss) for the period from discontinued operations (8-9)	179.5	462.9	(136.1)	(150.6)
11	Profit for the period (7+10)	3,359.5	6,448.0	1,221.6	12,304.1
12	Other comprehensive income				
	Items that will not to be reclassified subsequently to profit or loss:				
	(a) Re-measurement of defined benefit liability	19.6	11.2	5.6	78.4
	(b) Income-tax relating to items that will not be reclassified to profit or loss	(4.9)	(2.8)	(1.4)	(19.7)
	Other comprehensive income for the period	14.7	8.4	4.2	58.7
13	Total comprehensive income for the period (11+12)	3,374.2	6,456.4	1,225.8	12,362.8
14	Paid-up equity share capital (face value ₹ 1 per share)	585.9	585.9	585.9	585.9
15	Other equity				178,555.8
16	Earnings per equity share from continuing operations (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	5.43	10.22	2.32	21.26
	(b) Diluted (in ₹)	5.43	10.22	2.32	21.26
17	Earnings per equity share from discontinued operations (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	0.31	0.78	(0.24)	(0.26)
	(b) Diluted (in ₹)	0.31	0.78	(0.24)	(0.26)
18	Earnings per equity share for total operations (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	5.73	11.00	2.08	21.00
	(b) Diluted (in ₹)	5.73	11.00	2.08	21.00



K. S. S. S.



NOTES:

- 1 The above standalone financial results of Aurobindo Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 12, 2023. The results for the quarter ended June 30, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2023.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceutical Products'.
- 4 The Board of Directors of the Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS). Consequently the Company entered into share subscription and purchase agreement and obtained control (51%) w.e.f August 17, 2022.
- 5 The Board of Directors of the Company at its meeting held on February 9, 2023 and April 01, 2023 approved the transfer of certain Active Pharmaceutical Ingredients (API) business units (Unit I, VIII, IX, XI, XIV, RC- 2, V and XVII) to its wholly owned subsidiary, Apitoria Pharma Private Limited (APPL) (formerly known as Auro Pharma India Private Limited) on a going concern basis by way of a slump sale w.e.f April 01, 2023 subject to certain conditions precedent including receipt of requisite approvals. The Company is co-ordinating with relevant regulatory agencies for formalities to be completed for the proposed transfer.

Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for all the periods have been suitably presented.

Key financials information of discontinued Operations:

Particulars	Quarter ended			Year ended	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023	
Total income	11,207.4	11,494.2	10,461.0	43,260.8	
Total expenses	10,966.9	10,908.4	10,650.5	43,458.4	
Profit/(loss) before tax	240.5	585.8	(189.5)	(197.6)	
Total tax expense	61.0	122.9	(53.4)	(47.0)	
Net profit/(loss) for the period	179.5	462.9	(136.1)	(150.6)	

- 6 The figures for the quarter ended March 31, 2023 are the balancing figures of the audited financials for the year ended March 31, 2023 and unaudited the year to date published results for the nine months ended December 31, 2022, which were subject to limited review by the statutory auditors.



By Order of the Board

K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : August 12, 2023

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **AUROBINDO PHARMA LIMITED** ("the Company"), for the quarter ended June 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



C Manish Muralidhar
(Partner)
(Membership No. 213649)

Place: Hyderabad
Date: August 12, 2023
UDIN: 23213649BGVCAZ5744




AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ millions, unless otherwise stated)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023				
Particulars	Quarter ended			Year ended
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited (Refer note 8)	Unaudited	Audited
1 Revenue from operations				
(a) Net sales/ income from operations	67,906.4	63,786.7	61,768.4	246,171.3
(b) Other operating income	598.8	942.9	590.8	2,382.5
Total revenue from operations	68,505.2	64,729.6	62,359.2	248,553.8
2 Other income				
(a) Foreign exchange gain (net)	376.8	226.5	-	-
(b) Others	786.5	1,122.6	406.2	2,905.9
Total other income	1,163.3	1,349.1	406.2	2,905.9
Total income (1+2)	69,668.5	66,078.7	62,765.4	251,459.7
3 Expenses				
(a) Cost of materials consumed	27,568.3	26,705.7	20,117.1	96,525.1
(b) Purchase of stock-in-trade	5,801.6	5,887.5	4,890.5	20,504.3
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,822.8)	(3,283.5)	3,859.4	(4,096.8)
(d) Employee benefits expense	9,519.7	8,519.0	8,801.8	35,222.5
(e) Finance costs	565.5	556.0	146.3	1,404.8
(f) Foreign exchange loss (net)	-	-	282.6	395.8
(g) Depreciation and amortisation expense	3,265.6	3,455.7	2,795.1	12,445.8
(h) Other expenses	15,924.7	16,879.1	15,043.0	62,816.5
Total expenses	60,822.6	58,719.5	55,935.8	225,218.0
4 Profit before share of profit of associates and joint ventures, exceptional items	8,845.9	7,359.2	6,829.6	26,241.7
5 Share of loss of associates and joint ventures, net of tax	(28.1)	(58.6)	(39.7)	(116.7)
6 Profit before exceptional items and tax (4+5)	8,817.8	7,300.6	6,789.9	26,125.0
7 Exceptional items (refer note 4)	697.5	-	-	-
8 Profit before tax (6-7)	8,120.3	7,300.6	6,789.9	26,125.0
9 Tax expense				
Current tax	3,404.7	5,803.9	1,891.0	10,714.8
Deferred tax	(981.5)	(3,562.4)	(304.9)	(3,866.3)
Total tax expense	2,423.2	2,241.5	1,586.1	6,848.5
10 Profit for the period (8-9)	5,697.1	5,059.1	5,203.8	19,276.5
11 Other comprehensive Income				
A) Items that will not be reclassified subsequently to profit or loss:				
i) Re-measurement of defined employee benefit liability	19.6	7.5	3.6	79.4
ii) Equity investments through other comprehensive income – net change in fair value	(27.8)	22.3	(61.4)	(65.8)
iii) Income-tax relating to items that will not be reclassified to profit or loss	11.9	(0.9)	(1.4)	(19.5)
B) Items that will be reclassified subsequently to profit or loss:				
i) Exchange differences on translating the financial statements of foreign operations	(307.4)	101.9	1,829.8	7,361.7
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-
Total other comprehensive income/(loss) for the period (net of tax)	(303.7)	130.8	1,770.6	7,355.8
12 Total comprehensive income for the period (net of tax) (10+11)	5,393.4	5,189.9	6,974.4	26,632.3
Attributable to:				
Owners of the Holding Company	5,403.8	5,193.5	6,976.0	26,630.8
Non-controlling interest	(10.4)	(3.6)	(1.6)	1.5
Out of total comprehensive income above,				
Profit for the year attributable to:				
Owners of the Holding Company	5,707.5	5,062.7	5,205.4	19,275.0
Non-controlling interest	(10.4)	(3.6)	(1.6)	1.5
Other comprehensive income/(loss) attributable to:				
Owners of the Holding Company	(303.7)	130.8	1,770.6	7,355.8
Non-controlling interest	-	-	-	-
13 Paid-up equity share capital (face value ₹ 1 per share)	585.9	585.9	585.9	585.9
14 Other equity				267,812.6
15 Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
(a) Basic (in ₹)	9.74	8.64	8.88	32.90
(b) Diluted (in ₹)	9.74	8.64	8.88	32.90



4



NOTES:

- 1 The above consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 12, 2023. The results for the quarter ended June 30, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2023.
- 4 During the current quarter, the Company announced that Auro PR Inc., a step-down wholly owned subsidiary based at Caguas, Puerto Rico, is undertaking restructuring of its facility to enhance production volume. The Group has accrued the severance pay due to the employees of Auro PR Inc., who are being retrenched owing to the said restructuring and disclosed the same as an exceptional item.
- 5 The Group operates in only one reportable segment viz., 'Pharmaceutical Products'.
- 6 The Board of Directors of the Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS). Consequently the Company entered into share subscription and purchase agreement and obtained control (51%) w.e.f August 17, 2022.
- 7 During the current quarter, Auro Vaccines Private Limited (Wholly owned subsidiary) acquired equity shares of Tergene Biotech Limited (Joint Venture) from Aurobindo Pharma Limited (Parent). Consequently, Tergene Biotech Limited became a joint venture of Auro Vaccines Private Limited w.e.f April 1, 2023.
- 8 The figures for the quarter ended March 31, 2023 are the balancing figures of the audited financials for the year ended March 31, 2023 and unaudited the year to date published results for the nine months ended December 31, 2022, which were subject to limited review by the statutory auditors.



By Order of the Board

K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : August 12, 2023

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint ventures for the quarter ended June 30, 2023 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 11 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of ₹ 32,872.6 million, total net profit after tax (net) of ₹ 2,316.1 million for the quarter ended June 30, 2023 and total comprehensive income (net) of ₹ 2,316.1 million for the quarter ended June 30, 2023, as considered in the statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

Deloitte Haskins & Sells

7. The unaudited consolidated financial results includes the interim financial information of 56 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect, total revenue of ₹ 8,956.0 million for the quarter ended June 30, 2023, total profit after tax (net) of ₹ 673.1 million for the quarter ended June 30, 2023 and total comprehensive income (net) of ₹ 673.1 million for the quarter ended June 30, 2023, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of ₹ 28.3 million for the quarter ended June 30, 2023 and total comprehensive loss of ₹ 28.3 million for the quarter ended June 30, 2023, as considered in the Statement, in respect of 2 associates and 6 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

C Manish Muralidhar
Partner
(Membership No. 213649)

Place: Hyderabad
Date: August 12, 2023
UDIN: 23213649BGVCBA1365



Annexure I to the Independent Auditor's Review Report on Review of Interim Unaudited Consolidated Financial Results

The unaudited interim financial results include results of the following entities:

S.No	Name of Component	Country	Relationship
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auronext Pharma Private Limited	India	Direct Subsidiary
9	Auro Peptides Ltd	India	Direct Subsidiary
10	Apitoria Pharma Private Limited (formerly Auro Pharma India Private Limited)	India	Direct Subsidiary
11	Auroactive Pharma Private Limited	India	Direct Subsidiary
12	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
13	AuroZest Private Limited	India	Direct Subsidiary
14	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
15	Eugia Pharma Specialities Ltd	India	Direct Subsidiary
16	Mviyes Pharma Ventures Private Limited	India	Direct Subsidiary
17	Auro Vaccines Private Limited	India	Direct Subsidiary
18	GLS Pharma Private Limited (w.e.f August 17, 2022)	India	Direct Subsidiary
19	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
20	Laboratorios Aurobindo S.L.	Spain	Step-Down Subsidiary
21	Aurex B.V.(formerly known as Pharmacin B.V)	The Netherlands	Step-Down Subsidiary
22	Milpharm Limited	U.K	Step-Down Subsidiary
23	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
24	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
25	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
26	Pharmacin B.V. (formerly known as Aurex B.V)	The Netherlands	Step-Down Subsidiary
27	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
28	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
29	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
30	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
31	Arrow Generiques SAS	France	Step-Down Subsidiary
32	1980 Puren Pharma GmbH (formerly Actavis Management GmbH), Germany	Germany	Step-Down Subsidiary
33	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Step-Down Subsidiary
34	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Step-Down Subsidiary
35	Aurobindo Pharma B.V. (Formerly known as Actavis B.V)	The Netherlands	Step-Down Subsidiary
36	Aurovitas Spol s.r.o (formerly Apotex (CR) Spol s.r.o)	Czech Republic	Step-Down Subsidiary
37	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
38	Aurovitas Nederland B.V (formerly Apotex Nederland B.V.)	The Netherlands	Step-Down Subsidiary

Deloitte Haskins & Sells

S.No	Name of Component	Country	Relationship
39	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
40	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
41	Marel B.V.	The Netherlands	Step-Down Subsidiary
42	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
43	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
44	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
45	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
46	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
47	Eugia (UK) Limited	U.K	Step-Down Subsidiary
48	Auro Pharma Inc.	Canada	Step-Down Subsidiary
49	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
50	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
51	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
52	Aurobindo Pharma Colombia S A S	Colombia	Step-Down Subsidiary
53	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
54	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Step-Down Subsidiary
55	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
56	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
57	Aurosalud SA De CV	Mexico	Step-Down Subsidiary
58	Auro PR Inc	Puerto Rico	Step-Down Subsidiary
59	Eugia Pharma INC	Canada	Step-Down Subsidiary
60	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
61	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
62	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
63	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
64	PT Aurogen Pharma (w.e.f July 01, 2022)	Indonesia	Step-Down Subsidiary
65	Auroscience PTY Ltd	Australia	Step-Down Subsidiary
66	Aurolife Pharma LLC	USA	Step-Down Subsidiary
67	Auro Health LLC	USA	Step-Down Subsidiary
68	Auro AR LLC	USA	Step-Down Subsidiary
69	Auro Vaccines LLC	USA	Step-Down Subsidiary
70	AuroLogistics LLC	USA	Step-Down Subsidiary
71	Acrotech Biopharma Inc (formerly Acrotech Biopharma LLC)	USA	Step-Down Subsidiary
72	Auro Science LLC	USA	Step-Down Subsidiary
73	Auro Packaging LLC	USA	Step-Down Subsidiary
74	Vespyr Brands, Inc (formerly known as Nurya Brands Inc)	USA	Step-Down Subsidiary
75	Eugia Inc	USA	Step-Down Subsidiary
76	Eugia US LLC(formerly known as Auro medics Pharma LLC)	USA	Step-Down Subsidiary
77	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
78	Eugia Steriles Private Limited (formerly known as Auro Cure Private Limited)	India	Step-Down Subsidiary
79	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
80	Qule Pharma Private Limited	India	Step-Down Subsidiary

Deloitte Haskins & Sells

S.No	Name of Component	Country	Relationship
81	Eugia SEZ Private Limited (Formerly Wytells Pharma Private Limited)	India	Step-Down Subsidiary
82	TheraNyM Biologics Private Limited (w.e.f September 22, 2022)	India	Step-Down Subsidiary
83	Novagen Pharma (Pty) Ltd	South Africa	Joint venture
84	Purple Bellflower, South Africa	South Africa	Joint venture
85	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
86	Novagen BBBEE Invest Co (Pty) Ltd	South Africa	Joint venture
87	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Ltd)	India	Joint venture
88	Tergene Biotech Limited (formerly Tergene Biotech Pvt. Ltd)	India	Joint venture
89	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
90	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate

✓ ✓